文献速递心力衰竭与心肌病

糖尿病与心力衰竭进展:ARIC研究

Diabetes and Progression of Heart Failure: The Atherosclerosis Risk In Communities (ARIC) Study.
PubMed 文献 · J Am Coll Cardiol · 2022-01-01

该研究纳入ARIC研究第5次随访(2011-2013年)的4774名临床前心衰(A期或B期)成人,评估糖尿病及血糖控制(HbA1C <7% vs ≥7%)与心衰进展的关联。随访8.6年期间发生470例心衰事件。B期且HbA1C≥7%者发生临床心衰的年龄更轻,且与A期无糖尿病者相比心衰进展风险显著增加(HR 7.56,95%CI 4.68-12.20)。

要点

  • B期临床前心衰合并血糖控制不佳者心衰进展风险显著高于A期无糖尿病者(HR 7.56)。
  • HbA1C≥7%与B期心衰进展的关联(HR 1.83)强于A期(HR 1.52)。
  • B期伴HbA1C≥7%者发生临床心衰的年龄(80岁)早于血糖控制者(83岁)或无糖尿病者(82岁)。

核心结论

  • 在临床前心衰阶段的老年人中,未控制的糖尿病与显著的心衰进展风险相关。
  • 结果提示在心衰进程早期针对糖尿病进行干预至关重要。

研究设计与样本

  • 基于ARIC研究第5次随访(2011-2013年)的队列分析,纳入4774名临床前心衰成人(A期n=1551,B期n=3223)。
  • 在A期和B期内分别评估糖尿病及血糖控制(HbA1C <7% vs ≥7%)与心衰进展的关联。

主要发现

  • 随访8.6年期间共发生470例心衰事件。
  • B期伴HbA1C≥7%者发生临床心衰的平均年龄为80岁,控制糖尿病者为83岁,无糖尿病者为82岁(P < 0.001)。
  • HbA1C≥7%与心衰的关联在B期(HR 1.83;95% CI 1.33-2.51)强于A期(HR 1.52;95% CI 0.53-4.38)。
  • B期且HbA1C≥7%者与A期无糖尿病者相比,心衰进展风险增加(HR 7.56;95% CI 4.68-12.20)。

临床怎么用

  • 对临床前心衰(尤其B期)患者应早期识别并管理糖尿病,控制HbA1C至<7%可能有助于延缓心衰进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The influence of diabetes on progression from preclinical heart failure (HF) stages to overt HF is poorly understood. OBJECTIVES: The purpose of this study was to characterize the influence of diabetes on the progression from preclinical HF stages (A or B based on the 2021 Universal Definition) to overt HF. METHODS: We included 4,774 adults with preclinical HF (stage A [n = 1,551] or B [n = 3,223]) who attended the ARIC (Atherosclerosis Risk In Communities) study Visit 5 (2011-2013). Within each stage (A or B), we assessed the associations of diabetes and glycemic control (hemoglobin A1C [HbA1C] <7% vs ≥7%) with progression to HF, and of cross-categories of HF stages (A vs B), diabetes, and glycemic control with incident HF. RESULTS: Among the participants (mean age 75.4 years, 58% women, 20% Black), there were 470 HF events during 8.6 years of follow-up. Stage B participants with HbA1C ≥7% experienced clinical HF at a younger age than those with controlled diabetes or without diabetes (mean age 80 years vs 83 years vs 82 years; P < 0.001). HbA1C ≥7% was more strongly associated with HF in stage B (HR: 1.83; 95% CI: 1.33-2.51) compared with stage A (HR: 1.52; 95% CI: 0.53-4.38). In cross-categories of preclinical HF stage and HbA1C, participants with stage B and HbA1C ≥7% had increased risk of HF progression compared with stage A without diabetes (HR: 7.56; 95% CI: 4.68-12.20). CONCLUSIONS: Among older adults with preclinical HF stages, uncontrolled diabetes was associated with substantial risk of HF progression. Our results suggest that targeting diabetes early in the HF process is critical.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Echouffo-Tcheugui, Ndumele, Zhang, et al. Diabetes and Progression of Heart Failure: The Atherosclerosis Risk In Communities (ARIC) Study. J Am Coll Cardiol. 2022. PMID: 35680178. doi:10.1016/j.jacc.2022.03.378

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。